ATE298889T1 - Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung - Google Patents

Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung

Info

Publication number
ATE298889T1
ATE298889T1 AT00972027T AT00972027T ATE298889T1 AT E298889 T1 ATE298889 T1 AT E298889T1 AT 00972027 T AT00972027 T AT 00972027T AT 00972027 T AT00972027 T AT 00972027T AT E298889 T1 ATE298889 T1 AT E298889T1
Authority
AT
Austria
Prior art keywords
isoagglutinin
production
resin
regeneration
free blood
Prior art date
Application number
AT00972027T
Other languages
English (en)
Inventor
Sing N Chin
David J Hammond
Original Assignee
Vi Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23647483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE298889(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vi Technologies Inc filed Critical Vi Technologies Inc
Application granted granted Critical
Publication of ATE298889T1 publication Critical patent/ATE298889T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
AT00972027T 1999-10-08 2000-10-06 Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung ATE298889T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41585499A 1999-10-08 1999-10-08
PCT/US2000/027711 WO2001027623A2 (en) 1999-10-08 2000-10-06 Isoagglutinin-depleted blood compositions and methods of making same

Publications (1)

Publication Number Publication Date
ATE298889T1 true ATE298889T1 (de) 2005-07-15

Family

ID=23647483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00972027T ATE298889T1 (de) 1999-10-08 2000-10-06 Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung

Country Status (9)

Country Link
EP (1) EP1224462B1 (de)
JP (1) JP2003511468A (de)
AT (1) ATE298889T1 (de)
AU (1) AU1074601A (de)
CA (1) CA2385179A1 (de)
DE (1) DE60021098T2 (de)
ES (1) ES2240187T3 (de)
MX (1) MXPA02003517A (de)
WO (1) WO2001027623A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803315B2 (en) * 2001-10-05 2010-09-28 American Sterilizer Company Decontamination of surfaces contaminated with prion-infected material with gaseous oxidizing agents
US7001873B2 (en) * 2001-10-05 2006-02-21 Steris Inc. Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations
BRPI0408978B8 (pt) 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
ES2746381T3 (es) * 2003-04-08 2020-03-05 Novo Nordisk As Regeneración de fases estacionarias cromatográficas
EP1506809A1 (de) * 2003-08-11 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co. KG Regenerierung von hydrolyseempfindlichen Adsorptionsmatrizen
EP1506810A1 (de) * 2003-08-11 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Regenerierung von hydrolyseempfindlichen Adsorptionsmatrizen
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
WO2006126942A1 (en) * 2005-05-24 2006-11-30 Ge Healthcare Bio-Sciences Ab Regeneration of a chromatography matrix
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
US9102709B1 (en) * 2011-07-08 2015-08-11 Biogen Ma Inc. Regeneration of chromatography material
JP2015532919A (ja) 2012-09-26 2015-11-16 ボーン セラピューティクス エス．アー． 溶剤／界面活性剤処理された血漿（ｓ／ｄ血漿）を含む製剤及びその使用
FR3026950A1 (fr) * 2014-10-09 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de plasma universel
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
FR3035971A1 (fr) 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b
FR3035789A1 (fr) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies
US10697983B2 (en) 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies
US20170066839A1 (en) * 2015-09-08 2017-03-09 Merck Patent Gmbh Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies
US10697982B2 (en) * 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies
EP3254671B1 (de) 2016-06-10 2019-11-13 Octapharma AG Hochkonzentrierte immunglobulinzusammensetzung zur pharmazeutischen anwendung
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
CA3233933A1 (en) * 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Compositions and methods for reducing bioburden in chromatography
JP2024505100A (ja) * 2021-02-02 2024-02-02 バイオコン バイオロジクス リミテッド シリカベース逆相クロマトグラフィー材料の再生のためのプロセス
WO2025103611A1 (en) 2023-11-15 2025-05-22 Biotest Ag Method of manufacturing an igm containing composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664913A (en) * 1982-05-24 1987-05-12 Xoma Corporation Method for treating plasma for transfusion
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors

Also Published As

Publication number Publication date
WO2001027623A2 (en) 2001-04-19
EP1224462A2 (de) 2002-07-24
DE60021098D1 (de) 2005-08-04
JP2003511468A (ja) 2003-03-25
MXPA02003517A (es) 2004-09-10
DE60021098T2 (de) 2006-06-14
WO2001027623A3 (en) 2002-01-17
CA2385179A1 (en) 2001-04-19
EP1224462B1 (de) 2005-06-29
AU1074601A (en) 2001-04-23
ES2240187T3 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
DE60021098D1 (de) Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung
DE69929986D1 (de) Verfahren zur entfernung von hiv und anderen viren aus blut
ATE402753T1 (de) Reinigung von ionischen flüssigkeiten
WO2003104418A3 (en) Reconstituted polypeptides
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE69737294D1 (de) Verfahren zur abtrennung des alpha-1-proteinase inhibitors von einer cohn-paste, welche die fraktionen iv-1 + iv-4 enthält
DE69913320D1 (de) Verfahren zur behandlung von gas-strömen bei der polyolefinherstellung
DE60221838D1 (de) Verfahren zur herstellung von aufgeschäumten polypropylenharzteilchen
DE60042343D1 (de) Abtrennung von fibrinogen von plasmaproteasen
ATE497517T1 (de) Verfahren zur trennung von polyester von anderen materialien
WO2001087849A3 (en) Modulators of tnf- alpha signaling
DE60044933D1 (de) Trennung von plasmakomponenten
DE60320681D1 (de) Regenerator, verfahren zur herstellung des regenerators, system zur herstellung des regenerators und stirling-kältemaschine
DE69801548D1 (de) Verfahren zur Reinigung von 1,4-Butandiol durch Schmelzkristallisation
ATE434036T1 (de) Filtrationsverfahren zur trennung von viren
DE69820580D1 (de) Verfahren zur Abtrennung von Metallen durch micellare Ultrafiltration, geeignet zur Behandlung von radioaktiven Abfallstoffen
EP1501511A4 (de) Verfahren zur behandlung von glaukom und anderen erkrankungen, die durch nos-2 expression vermittelt werden, durch hemmung des egfr-wegs
ATA57598A (de) Neues salz von 7-(2-(aminothiazol-4yl)-2-
Burnouf Current status and new developments in the production of plasma derivatives
DK1101735T3 (da) Fremgangsmåde til fjernelse af skabelonmidlet fra syntetiske zeolitter
IL175027A0 (en) Virally-safe factor viii with a low content of higher multimers
DE69811899D1 (de) Verfahren zum herstellen von methylmethacrylat
DE59912502D1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid
DE60226931D1 (de) Verfahren zur Herstellung von Polyester, Verfahren zur Herstellung von substituierter alpha-Hydroxycarbonsäure und Clostridium beijerinckii-Stamm HICA432

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1224462

Country of ref document: EP

RZN Patent revoked